RELEXXII extended-release methylphenidate HCl for ADHD
RELEXXII Solves the Dose Gap with 45 mg and
63 mg Strengths
Finding the right dose in ADHD treatment can be easier with smaller, 9 mg adjustments.1,2
Why choose RELEXXII?
-
Only branded
methylphenidate HCl to
offer 45 mg and 63 mg
strengths -
Unique Osmodex
Technology releases
RELEXXII at a
controlled rate -
Symptom relief within
an hour and maintained
throughout the day -
Savings offers to help
reduce out-of-pocket
costs
What is RELEXXII?
RELEXXII (methylphenidate HCl extended-release tablets) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients 6 years of age and older.1
ADHD symptom control
that lasts all day
RELEXXII is an extended-release methylphenidate medication designed to support ADHD symptom control throughout the day using unique Osmodex Technology. Osmotic pressure gradually delivers medication to help support ADHD symptom control from morning through evening.
Flexible dosing to solve the dose gap
Finding the lowest effective dose of ADHD medication often requires careful dose adjustments to help balance ADHD symptom control and tolerability. Some methylphenidate medications are only available in limited strength increments.
RELEXXII offers a dosing range with 9 mg step adjustments, including 45 mg and 63 mg strengths, to support ADHD medication dose adjustments and individualized treatment for the lowest effective dose.
Support for access and affordability
Those starting or continuing ADHD medication may face access challenges with cost considerations or pharmacy
availability. RELEXXII provides resources to help support you.
Filling Your RELEXXII Prescription
Get tips to help ensure the pharmacy fills the RELEXXII prescription your doctor intended.
Pay as Little as $0 Per Month*
RELEXXII’s savings resources help eligible patients access their prescribed treatment for less.
References: 1. RELEXXII package insert. Vertical Pharmaceuticals, LLC. 2. Childress AC, et al. Clin Pharmacol Drug Dev. 2025;0(0):1-7.
*Co-pay assistance is applicable to prescription coverage for eligible commercially insured patients. Offer void where prohibited. No income restrictions apply. Other restrictions may apply. Offer effective 04/2024. Alora Pharmaceuticals, LLC reserves the right to rescind, revoke, or amend this offer without notice. For full terms and conditions, click here.
All individuals depicted are models used for illustrative purposes only.
ADHD=attention deficit hyperactivity disorder